Bucksave, I wouldn't read too much into the phase 1 trial for SAN-300 not moving the stock. Phase 1 trial: "The objectives of the study are to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of SAN-300. The company expects to complete this Phase I clinical study with SAN-300 in the first half of 2012."
Stockholders probably view it as a drag on cash and will take a year just to complete Phase 1. Then it will have to push through Phase 2 and Phase 3 and that is quite a tall order. I'm not panning SAN-300 as a drug, and it may prove fruitful or it may not (too soon to place too much hope in it, and luckily we can watch it develop as the other revenue drivers mature and grow).
The main drivers over the next couple years will continue to be growing sales of current products, and hopefully advancement of Rhucin and Budesinide MMX to the market. If these things work out the rest is a bonus. I hope SAN-300 will succeed, but if not SNTS may be able to bring in some other late stage products if things work out.
CRUD, stock leaving before I could load up the trunk with big blocks of shares. Bucksave, should be getting happier. I knew this was a great buy low $3's. No sense rambling on, my other posts are very clear about the prospects for SNTS as a great investment.